06-08-2024 |
AH |
|
HALO |
Halozyme Therapeutics, Inc. |
7,010 |
0.85 |
0.73 |
0.68 |
Halozyme Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlook [8/6/2024 4:06 PM] |
54.15 |
2.21 (4.25%) |
54.55 |
2.61 (5.03%) |
32.83 - 57.08 |
1,690,642 |
1,160,000 |
49,018 |
|
|
07-05-2024 |
AH |
|
HALO |
Halozyme Therapeutics |
5,059 |
0.71 |
0.69 |
0.00 |
Halozyme Therapeutics Non-GAAP EPS of $0.79 beats by $0.09, revenue of $195.88M misses by $3.77M [5/7/2024 4:03 PM] |
42.07 |
0.86 (2.09%) |
41.30 |
0.09 (0.22%) |
29.85 - 45.00 |
1,849,084 |
850,000 |
3,725 |
|
|
20-02-2024 |
AH |
|
HALO |
Halozyme Therapeutics, Inc. |
4,740 |
0.75 |
0.77 |
0.44 |
Halozyme Therapeutics Non-GAAP EPS of $0.82 misses by $0.01, revenue of $230.04M misses by $1.1M [2/20/2024 4:02 PM] |
38.35 |
2.35 (6.53%) |
37.74 |
1.74 (4.83%) |
29.85 - 51.45 |
2,197,947 |
1,040,000 |
11,621 |
|
|
06-11-2023 |
AH |
|
HALO |
Halozyme Therapeutics, Inc. |
4,520 |
0.69 |
0.67 |
0.70 |
Halozyme Therapeutics Non-GAAP EPS of $0.75 beats by $0.04, revenue of $216M in-line [11/6/2023 4:09 PM] |
38.72 |
3.46 (9.81%) |
34.75 |
-0.51 (-1.45%) |
29.85 - 59.46 |
1,784,974 |
880,000 |
31,400 |
|
|
08-08-2023 |
AH |
|
HALO |
Halozyme Therapeutics, Inc. |
5,580 |
0.68 |
0.59 |
0.50 |
Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.10, revenue of $221.04M beats by $21.09M [8/8/2023 4:04 PM] |
42.57 |
-0.74 (-1.71%) |
45.00 |
1.69 (3.90%) |
29.85 - 59.46 |
981,239 |
1,060,000 |
129 |
|
|
09-05-2023 |
AH |
4:00 PM ET (May 9) |
HALO |
Halozyme Therapeutics, Inc. |
4,200 |
0.43 |
0.44 |
0.43 |
Halozyme Therapeutics Non-GAAP EPS of $0.47 misses by $0.01, revenue of $162.14M misses by $13.38M [5/9/2023 4:04 PM] |
34.50 |
3.92 (12.82%) |
33.00 |
2.42 (7.91%) |
29.85 - 59.46 |
2,938,805 |
1,400,000 |
10,760 |
|
|
21-02-2023 |
AH |
4:00 PM ET (Feb 21) |
HALO |
Halozyme Therapeutics, Inc. |
6,660 |
0.44 |
0.43 |
0.39 |
Halozyme Therapeutics Non-GAAP EPS of $0.48 beats by $0.01, revenue of $181.5M misses by $10.55M [2/21/2023 4:03 PM] |
50.04 |
0.38 (0.77%) |
48.00 |
-1.66 (-3.34%) |
32.00 - 59.46 |
1,129,137 |
1,050,000 |
64,460 |
|
|
08-11-2022 |
AH |
4:00 PM ET (Nov 8) |
HALO |
Halozyme Therapeutics, Inc. |
6,550 |
0.70 |
0.49 |
0.52 |
Halozyme Therapeutics Non-GAAP EPS of $0.74 beats by $0.23, revenue of $208.98M beats by $17.81M [11/8/2022 4:11 PM] |
49.82 |
3.99 (8.71%) |
47.75 |
1.92 (4.19%) |
31.36 - 52.98 |
2,308,702 |
980,000 |
1,432 |
|
|
09-08-2022 |
AH |
4:00 PM ET (Aug 9) |
HALO |
Halozyme Therapeutics, Inc. |
6,830 |
0.50 |
0.47 |
0.63 |
Halozyme Therapeutics Non-GAAP EPS of $0.53, revenue of $152.37M; raises FY22 outlook [8/9/2022 4:06 PM] |
44.09 |
0.76 (1.75%) |
47.00 |
3.67 (8.47%) |
31.36 - 52.98 |
1,966,337 |
1,090,000 |
2,751 |
|
|
10-05-2022 |
AH |
4:00 PM ET (May 10) |
HALO |
Halozyme Therapeutics, Inc. |
5,410 |
0.43 |
0.44 |
0.34 |
Halozyme Therapeutics Non-GAAP EPS of $0.47 misses by $0.02, revenue of $117.3M misses by $10.95M [5/10/2022 4:02 PM] |
38.55 |
0.35 (0.92%) |
38.50 |
0.30 (0.79%) |
31.36 - 46.62 |
1,198,952 |
1,110,000 |
1,039 |
|
|
22-02-2022 |
AH |
4:00 PM ET (Feb 22) |
HALO |
Halozyme Therapeutics, Inc. |
4,650 |
0.39 |
0.35 |
0.50 |
Halozyme Therapeutics Non-GAAP EPS of $0.42 beats by $0.01, revenue of $102M beats by $2.31M [2/22/2022 4:05 PM] |
33.77 |
0.98 (2.99%) |
32.79 |
0.0 (0.00%) |
31.36 - 56.40 |
1,059,509 |
710,000 |
14,872 |
|
|
02-11-2021 |
AH |
4:00 PM ET (Nov 2) |
HALO |
Halozyme Therapeutics, Inc. |
5,440 |
0.52 |
0.42 |
0.25 |
Halozyme Therapeutics EPS beats by $0.07, beats on revenue [11/2/2021 4:07 PM] |
40.05 |
0.56 (1.42%) |
40.66 |
1.17 (2.96%) |
30.07 - 56.40 |
1,181,948 |
670,000 |
8,792 |
|
|
09-08-2021 |
AH |
4:00 PM ET (Aug 9) |
HALO |
Halozyme Therapeutics, Inc. |
5,760 |
0.63 |
0.43 |
0.19 |
Halozyme Therapeutics EPS beats by $0.22, beats on revenue [8/9/2021 4:05 PM] |
41.31 |
0.87 (2.15%) |
46.00 |
5.56 (13.75%) |
25.17 - 56.40 |
1,663,589 |
720,000 |
126,793 |
|
|
10-05-2021 |
AH |
4:00 PM ET (May 10) |
HALO |
Halozyme Therapeutics, Inc. |
6,830 |
0.34 |
0.31 |
-0.04 |
Halozyme Therapeutics EPS beats by $0.05, beats on revenue [5/10/2021 4:03 PM] |
42.69 |
-3.41 (-7.41%) |
45.32 |
-0.78 (-1.69%) |
22.11 - 56.40 |
2,123,597 |
850,000 |
106 |
|
|
23-02-2021 |
AH |
4:00 PM ET (Feb 23) |
HALO |
Halozyme Therapeutics, Inc. |
6,720 |
0.50 |
0.56 |
-0.24 |
Halozyme Therapeutics EPS misses by $0.05, beats on revenue [2/23/2021 4:06 PM] |
51.87 |
4.66 (9.87%) |
48.99 |
1.78 (3.77%) |
12.71 - 56.40 |
10,413,487 |
1,016,394 |
35,757 |
|
|
02-11-2020 |
AH |
4:00 PM ET (Nov 2) |
HALO |
Halozyme Therapeutics, Inc. |
3,960 |
0.25 |
0.20 |
-0.17 |
Halozyme Therapeutics EPS beats by $0.05, beats on revenue [11/2/2020 4:05 PM] |
31.69 |
2.50 (11.58%) |
30.50 |
2.10 (7.39%) |
12.71 - 32.62 |
5,417,568 |
1,842,380 |
10,252 |
|
|
10-08-2020 |
AH |
4:00 PM ET (Aug 10) |
HALO |
Halozyme Therapeutics, Inc. |
3,980 |
0.19 |
0.25 |
-0.10 |
Halozyme Therapeutics EPS misses by $0.04, misses on revenue [8/10/2020 4:08 PM] |
28.92 |
0.28 (0.98%) |
27.59 |
-1.05 (-3.67%) |
12.71 - 29.64 |
587,832 |
845,797 |
1,688 |
|
|